Convalescent Plasma Therapy for Covid-19 Patients at RSUP Dr. Wahidin Sudirohusodo Makassar

Hitherto, there is no proper line of treatment for the new (nCOVID19). The development of unique antiviral drugs has taken precedence. Therapeutic antibodies () will be a significantly beneficial agent against nCOVID-19. Here the host immune responses to new discussed in this review provide strategy and further treatment and understanding of clinical interventions against nCOVID-19. Plasma therapy uses the antibodies found in the blood of people recovering (or convalesced) from an infection to treat infected patients. When an infection occurs, the body begins producing proteins specially made to kill the germ, called antibodies. Those antibodies coat specifically plasma in the blood of survivors, the yellow transparent liquid blood portion for months or even years. research assesses plasma use from Convalescent patients of infected with nCOVID-19 as a possible preventive treatment. But it is not yet recommended as a line of treatment, and it is used as a clinical trial in the new in Indian population.

Download Full-text

Plasma therapy a possible hope to fight against COVID-19

10.35543/osf.io/yhq7v ◽

2020 ◽

Author(s):

Ravikant Piyush ◽

Aroni Chatterjee ◽

Shashikant Ray

Keyword(s):

Middle East ◽

Severe Acute Respiratory Syndrome ◽

Viral Disease ◽

Plasma Therapy ◽

Therapeutic Drugs ◽

Wild Fire ◽

The World ◽

Short Span ◽

Game Changer

The world is currently going through a disastrous event and a catastrophic upheaval caused by the coronavirus disease 2019 (COVID-19). The pandemic has resulted in loss of more than 150000 deaths across the globe. Originating from China and spreading across all continents within a short span of time, it has become a matter of international emergency. Different agencies are adopting diverse approaches to stop and spread of this viral disease but still now nothing confirmatory has come up. Due to lack of vaccines and proper therapeutic drugs, the disease is still spreading like wild fire without control. An Old but very promising method- the convalescent plasma therapy could be the key therapy to stop this pandemic. This method has already proven its mettle on several occasions previously and has been found to be effective in curing the pandemics induced by Ebola, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the same group of β-Coronavirus that has resulted in the above diseases. Therefore, the role of plasma therapy is being explored for treatment of this disease. In this review, we have mainly focused on the role of convalescent plasma therapy and why its use should be promoted in fight against COVID-19, as it could turn out to be a game changer.

Download Full-text

The novel use of convalescent plasma in patients with COVID 19 in Basra governorate, Case series review

Iraqi National Journal of Medicine ◽

10.37319/iqnjm.2.csi.1 ◽

2020 ◽

pp. 1-10 ◽

Cited By ~ 1

Author(s):

Saad Hammadi ◽

Ali Hashim ◽

Abbas Ali ◽

Rafid Abbood ◽

Hassanein Ali ◽

...

Keyword(s):

Plasma Exchange ◽

Case Series ◽

Passive Immunity ◽

The Novel ◽

Efficacy And Safety ◽

Off Label Use ◽

Plasma Therapy ◽

Off Label ◽

Plasma Donation ◽

Patient Series

Background: The idea of convalescent plasma usage is to give passive immunity to the patients, so their immune system stands a good chance of combating the virus.this study will review 6 cases of eligible covid 19 patients that had been treated with convalescent plasma therapy in Basra covid 19 quarantine Objectives: to demonstrate efficacy and safety of convalescent plasma in the patient series that had been enrolled . Method: this study had pioneered a new method to collect up to 3,000 mL in one session by an off-label use of Spectra Optia Apheresis systems by TerumoBCT /Exchange set to collect convalescent plasma. In this study 250 mL convalescent plasma had been given each of the 6 patients, from one donor. respose in spo2,dyspnoea and tachypnoea was observed ,any reaction to plasma also had been monitored . Result: Our case series have demonstrated both safety and effectiveness of convalescent plasma. This study was successful in reaching our primary and secondary outcomes in all 6 patients (improvement in SpO2 and symptoms). With negligible difference in time of post transfusion response Conclusion: convalescent plasma is apperantly safe and effective, In this study 250 mL convalescent plasma had been given each of the 6 patients, from one donor using Therapeutic Plasma Exchange (TPE) protocol by Spectra Optia Apheresis system/TerumoBCT. Keywords: convalescent plasma, COVID-19, SARS CoV-2, apheresis, plasma exchange, plasma donation

Download Full-text

Clinical Characteristics and Convalescent Plasma Therapy in Severe and Critically Ill COVID-19 Patients

SSRN Electronic Journal ◽

10.2139/ssrn.3576894 ◽

2020 ◽

Cited By ~ 2

Author(s):

Xiaowei Yang ◽

Yi Sui ◽

Fangfang Liu ◽

Zhanfang Kang ◽

Shangling Wu ◽

...

Keyword(s):

Critically Ill ◽

Clinical Characteristics ◽

Plasma Therapy

Download Full-text

A Brief outlook on possible available solutions, therapies and suggestions for COVID-19

Coronaviruses ◽

10.2174/2666796701999200905094726 ◽

2020 ◽

Vol 01 ◽

Author(s):

Rashmi Saxena Pal ◽

Yogendra Pal ◽

Pranay Wal ◽

Ankita Wal ◽

Nikita Saraswat

Keyword(s):

United States ◽

Plasma Therapy ◽

Social Distancing ◽

The Past ◽

Antiviral Compounds ◽

Global Pandemic ◽

Case Count ◽

Current Scenario ◽

Hiv Drugs

Background: WHO declared COVID-19 a global pandemic. New cases are being added every day, as the case count in United States are to the maximum. No drugs or biologics are yet found to be effective for the prevention or treatment of COVID-19. Objective: To discuss the possibilities of available treatments available. Materials & Methods: Brief out-look is undertaken over the past issues available over the similar situations occurred with respect to the current scenario and prospectives. Results: There can be various possibilities in form of convalescent plasma therapy. The known drugs as HIV drugs, antimalarial medicines and antiviral compounds can serve as suggestive option. Conclusion: Till a confirm medicine or vaccine is sorted out for Covid-19, we need to take natural immune-boosters, along with precautionary steps, social distancing and other preventions as instructed for the benefit of everyone with an optimistic mind and attitude.

Download Full-text

Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome

The Hematology Journal ◽

10.1038/sj.thj.6200126 ◽

2001 ◽

Vol 2 (5) ◽

pp. 352-354 ◽

Cited By ~ 8

Author(s):

Agnès Veyradier ◽

François Brivet ◽

Martine Wolf ◽

Catherine Boyer-Neumann ◽

Bernadette Obert ◽

...

Keyword(s):

Hemolytic Uremic Syndrome ◽

Von Willebrand Factor ◽

Plasma Therapy ◽

Uremic Syndrome ◽

Von Willebrand ◽

Willebrand Factor

Download Full-text

Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review

International Journal of Clinical Transfusion Medicine ◽

10.2147/ijctm.s269691 ◽

2020 ◽

Vol Volume 8 ◽

pp. 7-21

Author(s):

Ishita Ray ◽

Diana Fiorela Sánchez ◽

Chris Andrea Robert ◽

Mary Phyllis Robert

Keyword(s):

Therapeutic Option ◽

Narrative Review ◽

Plasma Therapy ◽

Effective Therapeutic Option

Download Full-text

Successful treatment with eculizumab in a patient with pregnancy-associated atypical hemolytic uremic syndrome

Obstetric Medicine ◽

10.1177/1753495x211019902 ◽

2021 ◽

pp. 1753495X2110199

Author(s):

Mehmet Nuri Duran ◽

Fatma Beyazit ◽

Mesut Erbaş ◽

Onur Özkavak ◽

Celal Acar ◽

...

Keyword(s):

Haemolytic Uraemic Syndrome ◽

Gestational Hypertension ◽

Severe Renal Impairment ◽

Post Partum ◽

Atypical Hemolytic Uremic Syndrome ◽

Kidney Injury ◽

Rapid Improvement ◽

Plasma Therapy ◽

Elevated Liver Enzymes ◽

Atypical Haemolytic Uraemic Syndrome

Pregnancy‐associated atypical haemolytic uraemic syndrome is a rare and potentially lethal complement-mediated disorder. It can mimic preeclampsia, gestational hypertension, thrombotic thrombocytopenic purpura and hemolysis, elevated liver enzymes and low platelets syndrome. Thus, it can be hard to distinguish pregnancy‐associated atypical haemolytic uraemic syndrome from other causes in peri/post-partum women presenting with features of microangiopathic haemolytic anemia, thrombocytopenia and acute kidney injury. We present a case of a 35-year-old woman in her third pregnancy at 32 weeks’ gestation who underwent caesarean section due to fetal distress. She developed severe renal impairment, thrombocytopenia and neurologic symptoms within 24 hours after delivery. A diagnosis of pregnancy‐associated atypical haemolytic uraemic syndrome was provided, and treatment with plasma therapy followed by eculizumab was initiated. A rapid improvement of both clinical and laboratory parameters was observed. This case demonstrates the significance of early initiation of anti-complement therapy to prevent irreversible renal damage and possible death in women with pregnancy‐associated atypical haemolytic uraemic syndrome.

Download Full-text

Convalescent plasma therapy for COVID-19 patients: a protocol of a prospective meta-analysis of randomized controlled trials

Trials ◽

10.1186/s13063-021-05066-2 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Lajos Szakó ◽

Nelli Farkas ◽

Szabolcs Kiss ◽

Szilárd Váncsa ◽

Noémi Zádori ◽

...

Keyword(s):

Confidence Interval ◽

Randomized Controlled Trials ◽

Organ Failure ◽

Weighted Mean Difference ◽

Meta Analysis ◽

Controlled Trials ◽

Cochrane Central Register ◽

Plasma Therapy ◽

Monthly Basis ◽

Randomized Controlled

Abstract Background Coronavirus disease 2019 (COVID-19) is an infection with possible serious consequences. The plasma of recovered patients might serve as treatment, which we aim to assess in the form of a prospective meta-analysis focusing on mortality, multi-organ failure, duration of intensive care unit stay, and adverse events. Methods A systematic search was conducted to find relevant registered randomized controlled trials in five trial registries. A comprehensive search will be done continuously on a monthly basis in MEDLINE (via PubMed), Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to find the results of previously registered randomized controlled trials. The selection will be done by two independent authors. Data extraction will be carried out by two other independent reviewers. Disagreements will be resolved by a third investigator. An update of the search of the registries and the first search of the databases will be done on the 21st of July. Data synthesis will be performed following the recommendations of the Cochrane Collaboration. In the case of dichotomous outcomes (mortality and organ failure), we will calculate pooled risk ratios with a 95% confidence interval (CI) from two-by-two tables (treatment Y/N, outcome Y/N). Data from models with multivariate adjustment (hazard ratios, odds ratio, risk ratio) will be preferred for the analysis. P less than 0.05 will be considered statistically significant. In the case of ICU stay, weighted mean difference with a 95% confidence interval will be calculated. Heterogeneity will be tested with I2, and χ2 tests. Meta-analysis will be performed if at least 3 studies report on the same outcome and population. Discussion Convalescent plasma therapy is a considerable alternative in COVID-19, which we aim to investigate in a prospective meta-analysis.

Download Full-text

COVID‐19 convalescent plasma therapy: hit fast, hit hard!

Vox Sanguinis ◽

10.1111/vox.13091 ◽

2021 ◽

Cited By ~ 1

Author(s):

Daniele Focosi ◽

Massimo Franchini

Keyword(s):

Plasma Therapy

Download Full-text